EVOLVE Antiviral Initiative: Emetine for Dengue
This study, called EVOLVE Antiviral Initiative, is testing if Emetine Hydrochloride can help people with dengue fever. Dengue is a viral infection spread by mosquitoes, and currently, there isn't a specific medicine to treat it. This study aims to see if Emetine Hydrochloride, given as a pill, can reduce serious outcomes like death or severe dengue, and if it's safe to use. You might receive a 6mg dose of Emetine Hydrochloride, a 12mg dose, or a placebo (an inactive pill). To join, you must be between 18 and 65 years old, admitted to the hospital, and have a laboratory-confirmed dengue infection within the last 5 days. The study is planning to enroll 600 participants, but its current status is unclear.
- Study design
- This is an interventional study where participants will receive either Emetine Hydrochloride at two different doses or a placebo. It aims to enroll 600 participants.
- What's involved
- You would take a pill (either Emetine Hydrochloride or placebo) for 10 consecutive days. You would also have blood samples taken for at least 5 days to monitor your health.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess your health for up to 28 days after treatment to check for effectiveness and safety.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
At a glance
Conditions
NCT07016321
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Bharatpur Hospital
Bharatpur-10, Chitwan, Nepalstudy coordinator listed
Recruiting
Johns Hopkins University, Division of Infectious Disease
Baltimore, Marylandstudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Kunchok Dorjee, MBBS, PhD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate effectiveness of emetine in dengue patients assessed by 28-day mortality or progression28 days
28-day mortality or progression to severe dengue, defined as severe plasma leakage, severe bleeding, or severe organ involvement (death and severe dengue will be assessed as a composite outcome)
- Safety of emetine assessed by number of adverse eventsUp to 28 days
Record serious adverse events and toxicities by organ-system
- Safety of emetine assessed by rate of drug discontinuationUp to 28 days
Evaluate the safety of emetine assessed by rate of drug discontinuation